NCT01791517

Brief Summary

The purpose of this study is to evaluate the clinical and laboratory performance of three brand name contact lenses with three recently introduced multipurpose lens care solutions (test solutions) as well as a peroxide disinfecting solution (control solution).

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
269

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2013

Geographic Reach
3 countries

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2013

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

February 11, 2013

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 15, 2013

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2014

Completed
3.8 years until next milestone

Results Posted

Study results publicly available

November 6, 2017

Completed
Last Updated

June 19, 2018

Status Verified

October 1, 2017

Enrollment Period

1 year

First QC Date

February 11, 2013

Results QC Date

August 16, 2017

Last Update Submit

June 18, 2018

Conditions

Outcome Measures

Primary Outcomes (3)

  • Overall Comfort Score (Senofilcon A Lens)

    CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the senofilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).

    2-Week Follow-up

  • Overall Comfort Score (Galyfilcon A Lens)

    CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the galyfilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).

    2-Week Follow-up

  • Overall Comfort Score (Etafilcon A Lens)

    CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the etafilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).

    2-Week Follow-up

Study Arms (3)

Lens A (senofilcon A)

OTHER

Subjects randomized to Lens A will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).

Other: Solution 1 (Test)Other: Solution 2 (Test)Other: Solution 3 (Test)Other: Solution 4 (Control)

Lens B (galyfilcon A)

OTHER

Subjects randomized to Lens B will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).

Other: Solution 1 (Test)Other: Solution 2 (Test)Other: Solution 3 (Test)Other: Solution 4 (Control)

Lens C (etafilcon A)

OTHER

Subjects randomized to Lens C will be further randomized to 1 of 12 unique solution sequences; each subject will l receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).

Other: Solution 1 (Test)Other: Solution 2 (Test)Other: Solution 3 (Test)Other: Solution 4 (Control)

Interventions

Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order

Also known as: Revitalens
Lens A (senofilcon A)Lens B (galyfilcon A)Lens C (etafilcon A)

Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order

Also known as: Pure Moist
Lens A (senofilcon A)Lens B (galyfilcon A)Lens C (etafilcon A)

Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order

Also known as: Biotrue
Lens A (senofilcon A)Lens B (galyfilcon A)Lens C (etafilcon A)

Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order

Also known as: Clear Care
Lens A (senofilcon A)Lens B (galyfilcon A)Lens C (etafilcon A)

Eligibility Criteria

Age18 Years - 69 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • The subject must appear able and willing to adhere to the instruction set forth in this clinical protocol.
  • The subject must be between 18 and 69 years of age.
  • The subject must be willing to participate in a 9-month study.
  • The subject must require a visual correction in both eyes.
  • Subjective refraction must result in a vertex-corrected spherical contact lens prescription of +2.00D to -8.00D in each eye.
  • The subject must have best-corrected visual acuity of 0.20 or better in each eye.
  • The subject must be a current wearer of spherical soft contact lenses (no bifocal contact lenses or monovision) for at least 5 days/week and at least 8 hours/day during the month prior to enrollment.
  • The subject must require no more than -1.25D cylindrical correction in each eye after vertexing to the corneal plane.
  • The subject must have normal eye with no evidence of abnormality or disease that in the opinion of the investigator would contraindicate contact lens wear.

You may not qualify if:

  • Self-reported current pregnancy or lactation or plans to become pregnant during the study period (subjects who report becoming pregnant during the study will be discontinued).
  • Self-reported adverse reaction to a contact lens solution to be used in the study that in the opinion of the investigator would contraindicate use of that solution.
  • Any previous ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, etc.).
  • Any clinically meaningful slit lamp findings contraindicating contact lens wear (e.g. equal to or greater than Grade 3 finding of edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection, blepharitis/meibomian gland dysfunction) on the study specific classification scale or any other ocular abnormality that in the opinion of the investigator would contraindicate contact lens wear.
  • Any active ocular infection.
  • Current use of topical ophthalmic medications.
  • History of binocular vision abnormality or strabismus.
  • More than occasional use of dry eye/rewetting drops (more than 2 times per day on average).
  • Any infectious disease (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV) by self-report.
  • History of severe allergic reaction or anaphylaxis.
  • Other active ocular disease that in the opinion of the investigator would contraindicate contact lens wear.
  • Employee of the investigational clinic (e.g. investigator, coordinator, technician)
  • They have taken part in any other clinical trial or research, within two weeks prior to starting this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

University of Houston College of Optometry

Houston, Texas, 77204, United States

Location

University of Waterloo Centre for Contact Lens Research School of Optometry

Waterloo, Ontario, Canada

Location

University of Manchester, Department of Optometry & Neuroscience

Manchester, Lancashire, United Kingdom

Location

Related Publications (2)

  • Schulze MM, Srinivasan S, Hickson-Curran SB, Berntsen DA, Howarth GF, Toubouti Y, Morgan P, Nichols JJ, Jones LW; Performance of Contact Lens Solutions Study Group. Lid Wiper Epitheliopathy in Soft Contact Lens Wearers. Optom Vis Sci. 2016 Aug;93(8):943-54. doi: 10.1097/OPX.0000000000000919.

  • Berntsen DA, Hickson-Curran SB, Jones LW, Mathew JH, Maldonado-Codina C, Morgan PB, Schulze MM, Nichols JJ; Performance of Contact Lens Solutions Study Group. Subjective Comfort and Physiology with Modern Contact Lens Care Products. Optom Vis Sci. 2016 Aug;93(8):809-19. doi: 10.1097/OPX.0000000000000901.

Results Point of Contact

Title
Chantal Coles-Brennan, PRINCIPAL RESEARCH OPTOMETRIST, Global Med Affairs
Organization
Johnson & Johnson Vision Care, Inc.

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 11, 2013

First Posted

February 15, 2013

Study Start

February 1, 2013

Primary Completion

February 1, 2014

Study Completion

February 1, 2014

Last Updated

June 19, 2018

Results First Posted

November 6, 2017

Record last verified: 2017-10

Locations